Zacks.com on MSN5h
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMSSanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, ...
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosisDesignation is based on ...
Vir Biotechnology (NASDAQ:VIR) said its drugs tobevibart and elebsiran have received FDA Breakthrough Therapy designation for the treatment of chronic hepatitis delta. The drugs have also received ...
Kessler scientists' trial set to evaluate non-invasive brain stimulation for upper-extremity disability post-stroke, ...
French drug major Sanofi (SNY) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy ...
The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.
Vir Biotechnology's phase 3 hepatitis programs and cancer trials are on the horizon. Read why VIR stock could benefit from ...
Monroe Carell was a natural fit to offer the new therapy. Its multidisciplinary DMD Clinic, co-directed by Burnette, Soslow ...
A new study reveals how a single species of bacteria can sustain a diverse community of phage species, with implications for ...
The Irish News on MSN9d
Medical breakthrough as therapy unveiled for ‘untreatable’ debilitating illnessA man who does not wish to be named became the first person treated in the global trial a few weeks ago, receiving the ...
SER-155 is an oral, 16-strain microbiome therapeutic that works by decolonizing gastrointestinal pathogens, strengthening the epithelial barrier, and inducing immune tolerance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback